Invitrogen

BCL9L Polyclonal Antibody

4个已发表图片

3 篇参考文献

查看其他10个BCL9L抗体

抗体检测数据 (4)
已发表图片 (4)

BCL9L Antibody in Immunocytochemistry (ICC/IF)

BCL9L Antibody in Immunocytochemistry (ICC/IF)

图: 1 / 8

BCL9L Antibody (PA5-21111) in ICC/IF

Immunocytochemistry of Bcl9L in HeLa cells with BCL9L Polyclonal Antibody (Product # PA5-21111) at 10 µg/mL.

BCL9L Antibody in Immunocytochemistry (ICC/IF)

BCL9L Antibody in Immunohistochemistry (IHC)

BCL9L Antibody in Immunohistochemistry (IHC)

BCL9L Antibody in Western Blot (WB)

BCL9L Antibody in Immunocytochemistry (ICC/IF)

BCL9L Antibody in Immunocytochemistry, Immunohistochemistry (ICC/IF, IHC)

BCL9L Antibody in Western Blot (WB)

BCL9L Antibody in Western Blot (WB)

Product Image Gallery

BCL9L Antibody in Immunocytochemistry (ICC/IF) — Immunocytochemistry of Bcl9L in HeLa cells with BCL9L Polyclonal Antibody (Product # PA5-21111) at 10 µg/mL.

BCL9L Antibody in Immunohistochemistry (IHC) — Immunofluorescence of Bcl9L in human breast tissue with BCL9L Polyclonal Antibody (Product # PA5-21111) at 20 µg/mL. Green: Bcl9L Blue: DAPI staining

BCL9L Antibody in Immunohistochemistry (IHC) — Immunohistochemistry of Bcl9L in human breast tissue with BCL9L Polyclonal Antibody (Product # PA5-21111) at 5 µg/mL.

BCL9L Antibody in Western Blot (WB) — Western Blot analysis of Bcl9L in HeLa cell lysate with BCL9L Polyclonal Antibody (Product # PA5-21111) at 1 µg/mL in (A) the absence and (B) the presence of blocking peptide.

BCL9L Antibody in Immunocytochemistry (ICC/IF) — EV5 Figure BCL9L participates in regulating the stemness of soft tumor cells A The mRNA expression of BCL9L in stiff or soft B16, MP-1, 4T1, or MCF-7 cells was determined by real-time PCR. n = 3. B, C The stiff or soft B16, MP-1, 4T1, or MCF-7 cells were stained with anti-BCL9L (B) or anti-beta-catenin (C) and DAPI and observed under confocal microscope. The relative intensity was quantified. Scale bar, 10 mum. n = 10. D The expression of nuclear beta-catenin in stiff or soft 4T1, MCF-7, B16, or MP-1 cells was determined by Western blot. E SGGFP, BCL9L -SGs- 4T1, MCF-7, B16, or MP-1 cells were stained with anti-beta-catenin antibody and observed under confocal microscope. The relative intensity was quantified. Scale bar, 10 mum. n = 10. F 500 soft SGGFP or BCL9L -SGs-4T1, MCF-7, B16, or MP-1 cells were seeded in 90 Pa soft 3D fibrin gel for the indicated time periods. The colony size was measured. The colony size in D0 (day 0) was set to 1. n = 3. G The mRNA expression of Nestin, Nanog, OCT3/4, CD133, or SOX2 in stiff or soft SGGFP or BCL9L -SGs- B16, MP-1, 4T1, or MCF-7 cells was detected by real-time PCR. n = 3. H The 100 soft SGGFP or BCL9L -SGs-4T1 cells were injected into the mammary fat pads of NSG mice for 8 weeks. Then, mice were sacrificed and the lung sections were performed H&E stained. The metastasis index was calculated. n = 5 mice with metastatic tumor. Scale bar, 0.5 mm. I The Transwell invasion assay from soft SGGFP- or BCL9L -SGs- 4T1 or MP-1 cells. The numbe

BCL9L Antibody in Immunocytochemistry, Immunohistochemistry (ICC/IF, IHC) — 6 Figure BCL9L highly expressed in soft tumor cells from cancer patients The stiffness of primary breast (HBC, n = 3) and colon (HCC, n = 3) cancer cells screened from the outlet or backflow inlet was measured by AFM. n = 100 from each patient. The correlation between the percentage of soft primary tumor cells from patients with breast ( n = 11) or colon ( n = 23) cancer and the grade of breast or colon cancer, respectively. The stiff and soft tumor cells were isolated from 3 patients with breast cancer and stained with anti-BCL9L antibody. The expression of BCL9L was observed under confocal microscope. Scale bar, 10 mum. The tissue sections from 6 melanoma patients with high grades of cancer and 3 melanoma patients with low grade of malignancy were immunohistochemical staining with anti-BCL9L antibody. Scale bar, 50 mum. The correlation between the expression of BCL9L from 18 patients with melanoma and the grade of melanoma. Overall survival compared with the BCL9L level in patients with breast cancer (BRCA, n = 536) or melanoma ( n = 376). Data information: Mann-Whitney test (A), paired Student's t -test (C), Pearson's correlation test (B and E) or Log-rank survival analysis (F). The data represent mean +- SD.

BCL9L Antibody in Western Blot (WB) — Figure 5 BCL9L is the key mediator to regulate the stemness and tumorigenicity of soft tumor cells A The expression of BCL9L or beta-catenin in stiff or soft 4T1, MCF-7, B16, or MP-1 cells was determined by Western blot. B The expression of beta-catenin and BCL9L from SGGFP, BCL9L -SGs-4T1, MCF-7, B16, or MP-1 cells were determined by Western blot. C 500 soft SGGFP or BCL9L -SGs- 4T1, MCF-7, B16-F1, or MP-1 cells were seeded in a 90 Pa soft 3D fibrin gel for 6 days. The number of formed colonies was counted. n = 10. D The soft SGGFP or BCL9L -SGs- 4T1, MCF-7, B16, or MP-1 cells (100 cells) were injected into the mammary fat pads (4T1 and MCF-7) or subcutaneous tissue (B16 and MP-1) of NSG mice. Tumor formation was recorded. n = 10 or 12 mice as indicated. E, F The 100 soft SGGFP or BCL9L -SGs- 4T1, B16, or MP-1 cells were injected into the mammary fat pads (4T1) of BALB/c mice or tail vein (B16 and MP-1) of NSG mice. The tumor formation was recorded (E). Six to eight weeks later, the lung sections were H&E stained. The metastatic micronodules in the lung were counted, and the metastasis index was calculated (F). Scale bar, 0.5 mm. n = 3 (for B16-F1) or 5 (for MP-1) mice with metastatic tumor. Data information: Bonferroni test (C and F). The data represent mean +- SD. n = 3 independent experiments in (A and B). Source data are available online for this figure.

BCL9L Antibody in Western Blot (WB) — 5 Figure BCL9L is the key mediator to regulate the stemness and tumorigenicity of soft tumor cells A The expression of BCL9L or beta-catenin in stiff or soft 4T1, MCF-7, B16, or MP-1 cells was determined by Western blot. B The expression of beta-catenin and BCL9L from SGGFP, BCL9L -SGs-4T1, MCF-7, B16, or MP-1 cells were determined by Western blot. C 500 soft SGGFP or BCL9L -SGs- 4T1, MCF-7, B16-F1, or MP-1 cells were seeded in a 90 Pa soft 3D fibrin gel for 6 days. The number of formed colonies was counted. n = 10. D The soft SGGFP or BCL9L -SGs- 4T1, MCF-7, B16, or MP-1 cells (100 cells) were injected into the mammary fat pads (4T1 and MCF-7) or subcutaneous tissue (B16 and MP-1) of NSG mice. Tumor formation was recorded. n = 10 or 12 mice as indicated. E, F The 100 soft SGGFP or BCL9L -SGs- 4T1, B16, or MP-1 cells were injected into the mammary fat pads (4T1) of BALB/c mice or tail vein (B16 and MP-1) of NSG mice. The tumor formation was recorded (E). Six to eight weeks later, the lung sections were H&E stained. The metastatic micronodules in the lung were counted, and the metastasis index was calculated (F). Scale bar, 0.5 mm. n = 3 (for B16-F1) or 5 (for MP-1) mice with metastatic tumor. Data information: Bonferroni test (C and F). The data represent mean +- SD. n = 3 independent experiments in (A and B). Source data are available online for this figure.

产品信息

PA5-21111

应用

建议稀释比

已发表文章

免疫印迹 (WB)

1 µg/mL

查看1篇已发表文章 1篇已发表文章

免疫组化 (IHC)

5 µg/mL

查看1篇已发表文章 1篇已发表文章

免疫细胞化学 (ICC/IF)

10 µg/mL

查看1篇已发表文章 1篇已发表文章

产品规格

种属反应

Human

已发表种属

Mouse

宿主/亚型

Rabbit / IgG

分类

Polyclonal

类型

Antibody

抗原

A 20 amino acid peptide near the amino terminus of human Bcl9L.

查看免疫原

偶联物

Unconjugated Unconjugated Unconjugated

形式

Liquid

浓度

1 mg/mL

纯化类型

Antigen affinity chromatography

保存液

PBS

内含物

0.02% sodium azide

保存条件

Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C

运输条件

Ambient (domestic); Wet ice (international)

AB_11155014

产品详细信息

A suggested positive control is Hela cell lysate.

PA5-21111 can be used with blocking peptide PEP-1225.

靶标信息

Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

Product References

Cell softness regulates tumorigenicity and stemness of cancer cells.

The EMBO journal

Lv J,Liu Y,Cheng F,Li J,Zhou Y,Zhang T,Zhou N,Li C,Wang Z,Ma L,Liu M,Zhu Q,Liu X,Tang K,Ma J,Zhang H,Xie J,Fang Y,Zhang H,Wang N,Liu Y,Huang B

PA5-21111 was used in Western Blot, Immunocytochemistry to show that microfluidic devices can be used to sort marker-based heterogeneous cancer stem cells (CSC) into mechanically stiff and soft subpopulations.

Fri Jan 15 00:00:00 UTC 2021

Cell softness regulates tumorigenicity and stemness of cancer cells.

The EMBO journal

Lv J,Liu Y,Cheng F,Li J,Zhou Y,Zhang T,Zhou N,Li C,Wang Z,Ma L,Liu M,Zhu Q,Liu X,Tang K,Ma J,Zhang H,Xie J,Fang Y,Zhang H,Wang N,Liu Y,Huang B

PA5-21111 was used in Western Blot, Immunocytochemistry to show that microfluidic devices can be used to sort marker-based heterogeneous cancer stem cells (CSC) into mechanically stiff and soft subpopulations.

Fri Jan 15 00:00:00 UTC 2021

Cell softness regulates tumorigenicity and stemness of cancer cells.

The EMBO journal

Lv J,Liu Y,Cheng F,Li J,Zhou Y,Zhang T,Zhou N,Li C,Wang Z,Ma L,Liu M,Zhu Q,Liu X,Tang K,Ma J,Zhang H,Xie J,Fang Y,Zhang H,Wang N,Liu Y,Huang B

PA5-21111 was used in Western Blot, Immunocytochemistry to show that microfluidic devices can be used to sort marker-based heterogeneous cancer stem cells (CSC) into mechanically stiff and soft subpopulations.

Fri Jan 15 00:00:00 UTC 2021

Cell softness regulates tumorigenicity and stemness of cancer cells.

The EMBO journal

Lv J,Liu Y,Cheng F,Li J,Zhou Y,Zhang T,Zhou N,Li C,Wang Z,Ma L,Liu M,Zhu Q,Liu X,Tang K,Ma J,Zhang H,Xie J,Fang Y,Zhang H,Wang N,Liu Y,Huang B

PA5-21111 was used in Western Blot, Immunocytochemistry to show that microfluidic devices can be used to sort marker-based heterogeneous cancer stem cells (CSC) into mechanically stiff and soft subpopulations.

Fri Jan 15 00:00:00 UTC 2021

Cell softness regulates tumorigenicity and stemness of cancer cells.

The EMBO journal

Lv J,Liu Y,Cheng F,Li J,Zhou Y,Zhang T,Zhou N,Li C,Wang Z,Ma L,Liu M,Zhu Q,Liu X,Tang K,Ma J,Zhang H,Xie J,Fang Y,Zhang H,Wang N,Liu Y,Huang B

PA5-21111 was used in Western Blot, Immunocytochemistry to show that microfluidic devices can be used to sort marker-based heterogeneous cancer stem cells (CSC) into mechanically stiff and soft subpopulations.

Fri Jan 15 00:00:00 UTC 2021

生物信息学

蛋白别名: B-cell CLL/lymphoma 9-like protein; B-cell lymphoma 9-like protein; BCL9-like protein; nuclear co-factor of beta-catenin signalling; Protein BCL9-2

查看更多收起

基因别名: BCL9-2; BCL9L; DLNB11

查看更多收起

UniProt ID: (Human) Q86UU0

查看更多收起

Entrez Gene ID: (Human) 283149

查看更多收起

transcription coactivator activity beta-catenin binding

transcription, DNA-templated positive regulation of epithelial to mesenchymal transition regulation of cell morphogenesis negative regulation of transforming growth factor beta receptor signaling pathway somatic stem cell population maintenance skeletal muscle cell differentiation positive regulation of transcription from RNA polymerase II promoter canonical Wnt signaling pathway beta-catenin-TCF complex assembly